The US anti-inflammatory drugs market, valued at 39,800 Million USD in 2025, is forecasted to grow consistently through 2035. Factors contributing to revenue expansion include increased disease burden, therapy innovations, and wider insurance coverage. From 2020 to 2025, steady growth was observed due to biologics uptake and greater disease awareness. The post-2025 trajectory remains robust as the market embraces biosimilars, digital health integration, and novel drug delivery technologies, projected to exceed 68,200 Million USD by 2035.
Read More - https://bussinessinsights.com/research-report/us-anti-inflammatory-drugs
Rheumatoid arthritis remains the foremost application segment in 2025, driven by high prevalence and the chronic nature of the disease. Osteoarthritis is the next major contributor, emphasizing the need for effective pain and inflammation management across an aging population. Psoriasis and inflammatory bowel diseases collectively represent significant portions due to increasing diagnosis rates. The diversity in application segments illustrates the broad therapeutic impact and commercial opportunities within the anti-inflammatory drug market.
Request Free Sample- https://bussinessinsights.com/request/telecommunication/us-anti-inflammatory-drugs
Who are the key players in US Anti-inflammatory Drugs industry?
The key players in the US Anti-inflammatory Drugs industry include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb, and Amgen Inc. These companies lead the market with extensive portfolios, innovative drug development, significant research and development investments, and strategic partnerships to advance anti-inflammatory therapies.
What is the US Anti-inflammatory Drugs growth?
The US Anti-inflammatory Drugs market has experienced robust growth, driven by rising incidence of chronic inflammatory diseases. In 2023, AbbVie reported increased sales of its blockbuster drug Humira. The market's expansion is also supported by the launch of new biologics and strong demand for advanced treatment options.
Which segment accounted for the largest US Anti-inflammatory Drugs share?
The largest share of the US Anti-inflammatory Drugs market is held by the autoimmune diseases application segment, including rheumatoid arthritis and inflammatory bowel disease. This is due to the high prevalence of these conditions and increased use of biologic drugs to manage moderate-to-severe cases and improve patient outcomes.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com